Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis	Boehringer Ingelheim/ Balsam	Ongoing	Survodutide	2	1404-0044	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%	"Boehringer Ingelheim/ IQVIA "	Ongoing	Vicadrostat (BI 690517)/ Jardiance (BI 10773)	3	1378-0018	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies	Novartis /ArabMed	Ongoing	Rapcabtagene autoleucel (YTB323)	2	CYTB323L12201	King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-Label, Multi-Centre, Rollover Study to Characterise Long-Term Safety and Efficacy of Etavopivat In Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia And Have Completed A Treatment Period in An Etavopivat Study	Novo Nordisk	Ongoing	Etavopivat	3	NN7535-7822	Prince Mohammad Bin Naser Hospital (Jazan)
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis	Boehringer Ingelheim/ Balsam	Ongoing	Survodutide	3	1404-0064	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)	Rapcabtagene autoleucel (YTB323)	Ongoing	Rapcabtagene autoleucel (YTB323)	2	CYTB323J12201	King Faisal Specialist Hospital and Research Center (Riyadh)
Impact of an Oxygen-Loaded Sustained-Release Hyaluronic Acid Hydrogel on Periodontal Pocket Depth Reduction and Pain Control: A Split-Mouth Randomized Clinical Trial	PI Initiative	Ongoing	Hyaluronic acid and Oxygel gel	4	OHGel2025	Dental Hospital of King Khalid University (Abha)
An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers	AstraZeneca	Ongoing	Durvalumab	4	D419CR00035	King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors	Pfizer / MCT	Ongoing	Marstacimab	3	B7841007	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease	Merck sharp & Dohme	Ongoing	Tulisokibart	3	NCT0643080	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Hospital NG (Riyadh), King Saud University Medical City (Riyadh), King Abdullah Medical City Specialist Hospital (Makkah)